The Beacon
The Beacon

The Beacon

H. Jack West, MD

Overview
Episodes

Details

Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.

Recent Episodes

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)
MAR 8, 2019
Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer (BMIC-075)
Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the evidence on an optimal duration of immunotherapy for long-responding patients with advanced NSCLC, weighing efficacy, potential toxicity, and cost concerns.
play-circle icon
20 MIN
Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074)
MAR 5, 2019
Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting (BMIC-074)
Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the challenges of conducting clinical trials and delivering increasingly complex patient care, along with the possible future role of artificial intelligence and telemedicine.
play-circle icon
24 MIN
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
DEC 28, 2018
Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)
Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter.
play-circle icon
13 MIN
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
DEC 21, 2018
What does the CheckMate-331 trial of nivolumab vs. chemo for relapsed SCLC tell us? (BMIC-072)
Dr. Jack West reviews the trial design, key results, and implications of the CheckMate-331 trial of nivolumab (Opdivo) vs. standard chemotherapy for relapsed small cell lung cancer.
play-circle icon
9 MIN
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
DEC 11, 2018
The IMpower130 Trial of Carbo/Nab-Paclitaxel +/- Atezolizumab: Does this Positive Trial Change Management? (BMIC-071)
Dr. Jack West reviews the IMpower130 trial of carboplatin + nab-paclitaxel with or without atezolizumab as first line treatment for advanced non-squamous NSCLC and whether this positive trial changes management in this setting.
play-circle icon
10 MIN